NASDAQ: SNTI - Senti Biosciences, Inc.

半年間の収益性: +0.5128%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Senti Biosciences, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

さらに詳しく
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2022-06-09
ISIN US81726A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sentibio.com
Цена ао 0.412
1日あたりの価格変動: -5.31% (4.14)
週ごとの価格変動: -1.26% (3.97)
月ごとの料金変更: +83.18% (2.14)
3ヶ月間の価格変動: +73.45% (2.26)
半年間の価格変動: +0.5128% (3.9)
年間の価格変動: +493.94% (0.66)
3年間の価格推移: -60.32% (9.88)
5年間の価格推移: 0% (3.92)
10年間の価格推移: 0% (3.92)
年初からの価格変動: +84.91% (2.12)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
EV/EBITDA -0.4243 0
合計: 5

効率

名前 意味 学年
ROA, % -59.47 0
ROE, % -106.19 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.6122 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 2912.94 10
収益性 Ebitda, % 186.62 10
収益性 EPS, % 1244.77 10
合計: 10
さらに詳しく

機関 音量 共有, %
NEA Management Company, LLC 4426151 9.67
8vc Gp I, LLC 2537558 5.55
ARK Investment Management, LLC 1969860 4.31
Vanguard Group Inc 707052 1.55
Intel Corporation 595665 1.3
Triatomic Management Lp 310533 0.68
Geode Capital Management, LLC 238406 0.52
Omega Fund Management, Llc 195792 0.43
Bridgeway Capital Management, Inc. 145000 0.32
Artal Group S.A. 55555 0.12



スーパーバイザー 役職 支払い 生年
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 年)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 年)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 年)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 年)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

住所: United States, South San Francisco. CA, 2 Corporate Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.sentibio.com